Compare IDEXX Laboratories, Inc. (IDXX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Procter & Gamble Co — how do they compare? IDEXX Laboratories, Inc. trades at $559.64 (market cap $44.48B), while Procter & Gamble Co trades at $147.56 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 7.8× IDEXX Laboratories, Inc.'s market cap, and Procter & Gamble Co pays a 2.92% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PG | |
|---|---|---|
Market Cap | $44.48B | $347.26B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $167.18 |
52-Week Low | $520.87 | $138.10 |
Enterprise Value | $45.38B | $372.74B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Procter & Gamble (PG) trades at $148.00, down 1.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.41. Revenue reached $84.28 billion in 2025, with a net income margin of 19.16%. Recent developments include a partnership with the WNBA and ongoing dividend payments.
PG offers stable growth and reliable dividends, supported by strong cash flow and a 69-year dividend increase streak. Risks include premium valuation multiples and soft demand pressures. Analyst consensus is bullish with a $161.71 price target, suggesting potential upside from current levels amid moderate market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
